Published in Clin Cancer Res on January 14, 2013
EMT, CTCs and CSCs in tumor relapse and drug-resistance. Oncotarget (2015) 1.92
Emerging therapeutic biomarkers in endometrial cancer. Biomed Res Int (2013) 0.93
Prognostic role of hormone receptors in endometrial cancer: a systematic review and meta-analysis. World J Surg Oncol (2015) 0.87
Molecular profiling of circulating tumor cells links plasticity to the metastatic process in endometrial cancer. Mol Cancer (2014) 0.87
Molecular profiling of endometrial carcinoma precursor, primary and metastatic lesions suggests different targets for treatment in obese compared to non-obese patients. Oncotarget (2015) 0.86
Integration of molecular profiling and chemical imaging to elucidate fibroblast-microenvironment impact on cancer cell phenotype and endocrine resistance in breast cancer. PLoS One (2014) 0.86
Environmental immune disruptors, inflammation and cancer risk. Carcinogenesis (2015) 0.86
Deptor enhances triple-negative breast cancer metastasis and chemoresistance through coupling to survivin expression. Neoplasia (2015) 0.85
High level of HSF1 associates with aggressive endometrial carcinoma and suggests potential for HSP90 inhibitors. Br J Cancer (2014) 0.84
Distribution of estrogen and progesterone receptors isoforms in endometrial cancer. Diagn Pathol (2014) 0.84
Identification of estrogen receptor proteins in breast cancer cells using matrix-assisted laser desorption/ionization time of flight mass spectrometry (Review). Oncol Lett (2014) 0.83
Hypomethylation of the CTCFL/BORIS promoter and aberrant expression during endometrial cancer progression suggests a role as an Epi-driver gene. Oncotarget (2014) 0.82
Metformin inhibits 17β-estradiol-induced epithelial-to-mesenchymal transition via βKlotho-related ERK1/2 signaling and AMPKα signaling in endometrial adenocarcinoma cells. Oncotarget (2016) 0.81
Adjuvant therapy for endometrial cancer. J Gynecol Oncol (2014) 0.79
ATAD2 overexpression links to enrichment of B-MYB-translational signatures and development of aggressive endometrial carcinoma. Oncotarget (2015) 0.79
EFEMP1 is repressed by estrogen and inhibits the epithelial-mesenchymal transition via Wnt/β-catenin signaling in endometrial carcinoma. Oncotarget (2016) 0.79
Tumor necrosis is an important hallmark of aggressive endometrial cancer and associates with hypoxia, angiogenesis and inflammation responses. Oncotarget (2015) 0.78
Association of TGFBR2 rs6785358 Polymorphism with Increased Risk of Congenital Ventricular Septal Defect in a Chinese Population. Pediatr Cardiol (2015) 0.77
Switch in FOXA1 status associates with endometrial cancer progression. PLoS One (2014) 0.77
Disruptive environmental chemicals and cellular mechanisms that confer resistance to cell death. Carcinogenesis (2015) 0.77
Tissue and imaging biomarkers for hypoxia predict poor outcome in endometrial cancer. Oncotarget (2016) 0.77
Estrogen receptor-alpha as a predictive biomarker in endometrioid endometrial cancer. Gynecol Oncol (2016) 0.77
Integrative Protein-Based Prognostic Model for Early-Stage Endometrioid Endometrial Cancer. Clin Cancer Res (2015) 0.76
EMT-Inducing Molecular Factors in Gynecological Cancers. Biomed Res Int (2015) 0.76
Androgen receptor as potential therapeutic target in metastatic endometrial cancer. Oncotarget (2016) 0.75
Increased TET1 Expression in Inflammatory Microenvironment of Hyperinsulinemia Enhances the Response of Endometrial Cancer to Estrogen by Epigenetic Modulation of GPER. J Cancer (2017) 0.75
Recurrent hormone-binding domain truncated ESR1 amplifications in primary endometrial cancers suggest their implication in hormone independent growth. Sci Rep (2016) 0.75
Formal modeling and analysis of ER-α associated Biological Regulatory Network in breast cancer. PeerJ (2016) 0.75
Increased angiogenesis is associated with a 32-gene expression signature and 6p21 amplification in aggressive endometrial cancer. Oncotarget (2015) 0.75
Stromal Clues in Endometrial Carcinoma: Loss of Expression of β-Catenin, Epithelial-Mesenchymal Transition Regulators, and Estrogen-Progesterone Receptor. Int J Gynecol Pathol (2016) 0.75
Aneuploidy related transcriptional changes in endometrial cancer link low expression of chromosome 15q genes to poor survival. Oncotarget (2017) 0.75
Prognostic role of NF-YA splicing isoforms and Lamin A status in low grade endometrial cancer. Oncotarget (2016) 0.75
Endometrial cancer cells exhibit high expression of p110β and its selective inhibition induces variable responses on PI3K signaling, cell survival and proliferation. Oncotarget (2017) 0.75
Tamoxifen reverses epithelial-mesenchymal transition by demethylating miR-200c in triple-negative breast cancer cells. BMC Cancer (2017) 0.75
Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res (2004) 16.51
Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med (2008) 9.20
Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J Natl Cancer Inst (2003) 8.48
Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer. Cancer Discov (2011) 4.80
A model of human tumor dormancy: an angiogenic switch from the nonangiogenic phenotype. J Natl Cancer Inst (2006) 4.44
Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nat Genet (2013) 4.35
EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast. J Clin Oncol (2005) 4.24
Integrated genome-wide DNA copy number and expression analysis identifies distinct mechanisms of primary chemoresistance in ovarian carcinomas. Clin Cancer Res (2009) 3.45
GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer. Nat Genet (2013) 3.42
Drug-sensitive FGFR2 mutations in endometrial carcinoma. Proc Natl Acad Sci U S A (2008) 3.30
Axl is an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survival. Proc Natl Acad Sci U S A (2009) 3.29
Malignant melanoma--diagnosis, treatment and follow-up in Norway. Tidsskr Nor Laegeforen (2013) 3.21
Role of angiogenesis in human tumor dormancy: animal models of the angiogenic switch. Cell Cycle (2006) 3.10
Use of immunohistochemical markers can refine prognosis in triple negative breast cancer. BMC Cancer (2007) 3.09
Triple-negative breast cancer: distinguishing between basal and nonbasal subtypes. Clin Cancer Res (2009) 2.91
A switch from E-cadherin to N-cadherin expression indicates epithelial to mesenchymal transition and is of strong and independent importance for the progress of prostate cancer. Clin Cancer Res (2007) 2.57
The prognostic implication of the basal-like (cyclin E high/p27 low/p53+/glomeruloid-microvascular-proliferation+) phenotype of BRCA1-related breast cancer. Cancer Res (2004) 2.38
Genome-wide association study identifies three new melanoma susceptibility loci. Nat Genet (2011) 2.29
Expression of enhancer of zeste homologue 2 is significantly associated with increased tumor cell proliferation and is a marker of aggressive breast cancer. Clin Cancer Res (2006) 2.10
Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance. Clin Cancer Res (2009) 2.04
Early detection of breast cancer based on gene-expression patterns in peripheral blood cells. Breast Cancer Res (2005) 2.00
Combined loss of PTEN and p27 expression is associated with tumor cell proliferation by Ki-67 and increased risk of recurrent disease in localized prostate cancer. Clin Cancer Res (2003) 1.96
Large-scale enhancer detection in the zebrafish genome. Development (2005) 1.88
Genome-wide association study identifies a common variant associated with risk of endometrial cancer. Nat Genet (2011) 1.84
A basal epithelial phenotype is more frequent in interval breast cancers compared with screen detected tumors. Cancer Epidemiol Biomarkers Prev (2005) 1.74
Independent prognostic impact of lymphatic vessel density and presence of low-grade lymphangiogenesis in cutaneous melanoma. Clin Cancer Res (2003) 1.74
Epigenetic analysis leads to identification of HNF1B as a subtype-specific susceptibility gene for ovarian cancer. Nat Commun (2013) 1.73
Gene expression profiles do not consistently predict the clinical treatment response in locally advanced breast cancer. Mol Cancer Ther (2006) 1.64
cAMP effector mechanisms. Novel twists for an 'old' signaling system. FEBS Lett (2003) 1.62
Markers for individualised therapy in endometrial carcinoma. Lancet Oncol (2012) 1.61
Genome-wide profiling of histone h3 lysine 4 and lysine 27 trimethylation reveals an epigenetic signature in prostate carcinogenesis. PLoS One (2009) 1.54
Placental cadherin and the basal epithelial phenotype of BRCA1-related breast cancer. Clin Cancer Res (2005) 1.51
Importance of P-cadherin, beta-catenin, and Wnt5a/frizzled for progression of melanocytic tumors and prognosis in cutaneous melanoma. Clin Cancer Res (2005) 1.49
The MDM2 promoter SNP285C/309G haplotype diminishes Sp1 transcription factor binding and reduces risk for breast and ovarian cancer in Caucasians. Cancer Cell (2011) 1.40
Prognostic impact of alterations in P-cadherin expression and related cell adhesion markers in endometrial cancer. J Clin Oncol (2004) 1.39
Identification and molecular characterization of a new ovarian cancer susceptibility locus at 17q21.31. Nat Commun (2013) 1.36
Profiles of genomic instability in high-grade serous ovarian cancer predict treatment outcome. Clin Cancer Res (2012) 1.35
The dynamics and prognostic potential of DNA methylation changes at stem cell gene loci in women's cancer. PLoS Genet (2012) 1.33
Secondary breast cancer: a 5-year population-based study with review of the literature. APMIS (2009) 1.33
Significance of PTEN alterations in endometrial carcinoma: a population-based study of mutations, promoter methylation and PTEN protein expression. Int J Oncol (2004) 1.31
Epithelial to mesenchymal transition of a primary prostate cell line with switches of cell adhesion modules but without malignant transformation. PLoS One (2008) 1.27
Prolonged dormancy of human liposarcoma is associated with impaired tumor angiogenesis. FASEB J (2006) 1.21
Gene expression in poorly differentiated papillary thyroid carcinomas. Thyroid (2006) 1.21
Vascular proliferation is important for clinical progress of endometrial cancer. Cancer Res (2006) 1.19
Stathmin overexpression identifies high-risk patients and lymph node metastasis in endometrial cancer. Clin Cancer Res (2011) 1.19
SNP285C modulates oestrogen receptor/Sp1 binding to the MDM2 promoter and reduces the risk of endometrial but not prostatic cancer. Eur J Cancer (2011) 1.19
Ki-67 expression is superior to mitotic count and novel proliferation markers PHH3, MCM4 and mitosin as a prognostic factor in thick cutaneous melanoma. BMC Cancer (2010) 1.18
A variant in FTO shows association with melanoma risk not due to BMI. Nat Genet (2013) 1.17
Hormone receptor loss in endometrial carcinoma curettage predicts lymph node metastasis and poor outcome in prospective multicentre trial. Eur J Cancer (2013) 1.17
Ca2+/calmodulin-dependent protein kinase II is required for microcystin-induced apoptosis. J Biol Chem (2001) 1.16
Tumor-vascular interactions and tumor dormancy. APMIS (2008) 1.16
GATA3 expression in estrogen receptor alpha-negative endometrial carcinomas identifies aggressive tumors with high proliferation and poor patient survival. Am J Obstet Gynecol (2008) 1.15
Suppression of heat shock protein 27 induces long-term dormancy in human breast cancer. Proc Natl Acad Sci U S A (2012) 1.12
Biologic markers in endometrial cancer treatment. APMIS (2009) 1.12
Prosaposin inhibits tumor metastasis via paracrine and endocrine stimulation of stromal p53 and Tsp-1. Proc Natl Acad Sci U S A (2009) 1.12
Proliferation of immature tumor vessels is a novel marker of clinical progression in prostate cancer. Cancer Res (2009) 1.11
Role of DNA methylation and epigenetic silencing of HAND2 in endometrial cancer development. PLoS Med (2013) 1.10
NATH, a novel gene overexpressed in papillary thyroid carcinomas. Oncogene (2002) 1.09
Frequency of the basal-like phenotype in African breast cancer. APMIS (2007) 1.09
High-throughput interrogation of PIK3CA, PTEN, KRAS, FBXW7 and TP53 mutations in primary endometrial carcinoma. Gynecol Oncol (2012) 1.06
Loss of PTEN expression is associated with metastatic disease in patients with endometrial carcinoma. Cancer (2002) 1.06
TMPRSS2:ERG fusion transcripts in urine from prostate cancer patients correlate with a less favorable prognosis. APMIS (2009) 1.06
Onconeural antibodies in sera from patients with various types of tumours. Cancer Immunol Immunother (2009) 1.06
ERG upregulation and related ETS transcription factors in prostate cancer. Int J Oncol (2007) 1.05
Melanoma prone families with CDK4 germline mutation: phenotypic profile and associations with MC1R variants. J Med Genet (2013) 1.04
Amplification of the 20q chromosomal arm occurs early in tumorigenic transformation and may initiate cancer. PLoS One (2011) 1.03
Tumor necrosis is associated with increased alphavbeta3 integrin expression and poor prognosis in nodular cutaneous melanomas. BMC Cancer (2008) 1.03
Prognostic importance of glomeruloid microvascular proliferation indicates an aggressive angiogenic phenotype in human cancers. Cancer Res (2002) 1.03
Elevated plasma growth differentiation factor-15 correlates with lymph node metastases and poor survival in endometrial cancer. Clin Cancer Res (2011) 1.03